蘑菇视频APP

CAMBRIDGE, Mass., February 10, 2021 鈥� 蘑菇视频APP, a unique life sciences innovation enterprise, today announced the appointments of Diego Miralles, MD, as CEO-Partner and CEO of LARONDE, a 蘑菇视频APP company, and Andrew Oh, as Senior Partner. Miralles is a veteran pharmaceutical and biotech leader who joins Flagship from Vividion Therapeutics, Inc. where he was Chief Executive Officer. Oh brings more than two decades of finance and pharmaceutical experience and most recently served as Chief Financial Officer of Flagship-originated Rubius Therapeutics.

鈥淚 am delighted that Diego and Andy have joined Flagship鈥檚 team of talented and experienced executives,鈥� said Noubar Afeyan, PhD., Founder and CEO of 蘑菇视频APP. 鈥淒iego is a proven leader and innovator, with industry expertise spanning corporate, scientific, drug development and entrepreneurial endeavors. Andy鈥檚 deep experience in finance and the biopharmaceutical industry, demonstrated in his tremendous leadership at Flagship-originated Rubius Therapeutics as CFO, will add tremendous value as he focuses his talents across the broader Flagship enterprise.鈥�

鈥淚 am thrilled to join 蘑菇视频APP鈥檚 extraordinary executive leadership team and look forward to helping drive the growth of innovative life sciences companies founded by Flagship,鈥� said Dr. Miralles. 鈥淭he collective science conceived and moved forward across the many Flagship companies is broader and more transformational than anything I鈥檝e ever seen.鈥� He added, 鈥淎s CEO of LARONDE, I am committed to building a world-class team that enables us to maximize its amazing potential. I look forward to sharing more about the company and its prodigious platform in the future.鈥�

鈥溎⒐绞悠礎PP has built a marquee team of biotech entrepreneurs, and I am delighted by the opportunity to help the enterprise build the life science companies of tomorrow鈥� said Mr. Oh. 鈥淔rom my experience with Rubius Therapeutics I have seen first-hand the remarkable and disruptive advances that the Flagship ecosystem is fueling, and I look forward to helping to contribute to the success of this national treasure of innovation.鈥�

About Diego Miralles

Miralles joins Flagship from his role as CEO of Vividion Therapeutics, Inc., a biotechnology company focused on the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. As CEO, he led a team that raised over $360 million in venture capital and two large partnerships with BMS/Celgene and Roche. Prior to this role, he was President of Adaptive Therapeutics, a division of Adaptive Biotechnologies focused on clinical therapeutic applications of TCR sequencing.

Miralles also spent eleven years at Johnson & Johnson, where he most recently served as Global Head of Johnson & Johnson Innovation. Miralles鈥� many achievements at J&J include leading Janssen鈥檚 Research and Early Development Unit in California and establishing the J&J Innovation Centers and Janssen/JLABS. Miralles was also Vice President of Clinical Development at Tibotec, a J&J company, where he led a team that put six drugs in the clinic, ultimately garnering five approvals, including PREZISTA庐 and INTELENCE庐. Earlier in his career, he served in R&D roles at Trimeris, Inc. and Triangle Pharmaceutical and as was an Assistant Professor at Duke University Medical Center.

Miralles received an M.D. from Universidad de Buenos Aires, Argentina and conducted his residency at the Mayo Clinic in Rochester, MN and his fellowship in Infectious Diseases at New York Hospital-Cornell University Medical Center.

About Andrew Oh

Andrew Oh comes to Flagship with more than 20 years of experience in finance and the biopharmaceutical industry. As Senior Partner, he will work closely with Origination Partners and Flagship鈥檚 NewCo CEOs on capital formation at both the fund and portfolio levels. Prior to joining Flagship, Oh served for three years as CFO of Rubius Therapeutics, a Flagship-originated company, where he raised $453M, including a $277M initial public offering, which at the time was the highest valued preclinical biotech IPO in Wall Street history. In addition, he negotiated the acquisition of Alexion Pharmaceuticals鈥� former manufacturing facility in Rhode Island for $8M and secured approximately $9M in state tax incentives.

Prior to Rubius, Oh spent a decade as a portfolio manager at Leerink and Fidelity, investing in pharmaceutical and biotechnology companies. While at Fidelity, Oh managed the Fidelity Select Pharmaceuticals Portfolio fund for seven years which was rated by Lipper as the number one global health/biotechnology fund based on his three-and-five-year performance and grew from approximately $160M to $1B during his tenure. In addition, Oh served as Fidelity鈥檚 senior analyst covering global pharmaceutical companies and worked in a similar role for eight years on Wall Street at other firms, including JPMorgan where he was an associate on the #1 Institutional Investor-rated U.S. Pharmaceutical team.

Mr. Oh received an M.B.A. from Northwestern University's Kellogg School of Management and a B.A. in Biology from Washington University in St. Louis.

About 蘑菇视频APP
蘑菇视频APP conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50 billion in aggregate value. To date, Flagship has deployed over $2.2 billion in capital toward the founding and growth of its pioneering companies alongside more than $18 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: ), Codiak BioSciences (NASDAQ: ) Denali Therapeutics (NASDAQ: ), Evelo Biosciences (NASDAQ: ), Foghorn Therapeutics (NASDAQ: ), Indigo Ag, Kaleido Biosciences (NASDAQ: ), Moderna (NASDAQ: ), Rubius Therapeutics (NASDAQ: ), Sana Biotechnology (NASDAQ: ), Seres Therapeutics (NASDAQ: ), and Sigilon Therapeutics (NASDAQ:).